High-dose ulinastatin during cardiopulmonary bypass significantly improved the PaO2/FiO2 ratio (F=657.3) and reduced lung injury incidence compared to no ulinastatin.
Cohort (n=94)
Objective To determine whether pre-treatment with high-dose ulinastatin provides enhanced postoperative oxygenation in patients who have undergone aortic valve surgery with moderate hypothermic cardiopulmonary bypass (CPB). Methods Patients who underwent aortic valve surgery with moderate hypothermic CPB were retrospectively evaluated. In total, 94 of 146 patients were included. The patients were classified into one of two groups: patients in whom ulinastatin (10,000 U/kg followed by 5,000 U/kg/h) was administered during CPB (Group U, n = 38) and patients in whom ulinastatin was not administered (Group C, n = 56). The PaO 2 /FiO 2 ratio was calculated at the following time points: before CPB (pre-CPB), 2 h after weaning from CPB (post-CPB), and 6 h after arrival to the intensive care unit (ICU-6). The incidence of a low PaO 2 /FiO 2 ratio was also compared among the time points. Results Group U showed a significantly higher PaO 2 /FiO 2 ratio (F(4, 89.0) = 657.339) and a lower incidence of lung injury (PaO 2 /FiO 2 ratio < 300) than Group C at the post-CPB and ICU-6 time points. Conclusion High-dose ulinastatin improved pulmonary oxygenation after CPB and in the early stages of the ICU stay in patients undergoing aortic valve surgery with CPB.
Rhee et al. (Sun,) conducted a cohort in Patients undergoing aortic valve surgery with moderate hypothermic cardiopulmonary bypass (n=94). High-dose ulinastatin vs. No ulinastatin was evaluated on PaO2/FiO2 ratio and incidence of low PaO2/FiO2 ratio (<300). High-dose ulinastatin during cardiopulmonary bypass significantly improved the PaO2/FiO2 ratio (F=657.3) and reduced lung injury incidence compared to no ulinastatin.